Adderall Lawsuit: Shire Settlement, Antitrust, and Telehealth Cases

Adderall lawsuits fall into four main groups: personal injury claims over cardiovascular and psychiatric harm, a $56.5 million federal settlement with manufacturer Shire Pharmaceuticals over deceptive marketing, antitrust cases accusing Shire of blocking generic competition, and a recent wave of criminal prosecutions against telehealth companies accused of illegally distributing tens of millions of stimulant pills. Each track has produced different outcomes, and some are still active.

Injury and Death Claims Against the Manufacturer

The earliest Adderall lawsuits came from patients and families who blamed the drug for serious cardiovascular events. By February 2006, the FDA had linked Adderall to roughly 50 deaths, and Shire updated its prescribing information to warn about sudden death and serious heart problems.¹ Between 1999 and 2003, at least 24 Adderall-related deaths had been reported to the agency.²

The alleged injuries in these cases include sudden cardiac death, heart attacks, strokes, arrhythmias, high blood pressure, hallucinations, psychosis, and aggression.¹ Children were disproportionately represented in the early death reports, and families of children who died after taking Adderall were among the first plaintiffs. FDA warnings flagged that patients with pre-existing structural heart abnormalities faced particularly elevated risks of sudden death.²

The $56.5 Million Shire Marketing Settlement

In September 2014, Shire Pharmaceuticals agreed to pay $56.5 million to resolve federal False Claims Act allegations that it had made false and misleading marketing claims about Adderall XR and other drugs. About $35.7 million went to the federal government and $20.8 million to state Medicaid programs.³

Between 2004 and 2007, according to the government, Shire sales representatives promoted Adderall XR as capable of “normalizing” children with ADHD without clinical data to support that claim. They also allegedly told physicians the drug would prevent poor academic performance, criminal behavior, traffic accidents, and sexually transmitted diseases, and pushed it for conduct disorder, a use the FDA had never approved.³

The case grew out of whistleblower complaints filed under the False Claims Act’s qui tam provisions. Dr. Gerardo Torres, a former Shire executive, received $5.9 million from the settlement, and three former sales representatives were relators in a separate related case.³ As part of the deal, Shire entered a Corporate Integrity Agreement with the Department of Health and Human Services requiring enhanced compliance oversight and board-level certifications of its promotional practices.⁴ Shire did not admit liability.

Antitrust Lawsuits Over Generic Adderall XR

A separate line of cases accused Shire of using anti-competitive tactics to keep cheaper generic Adderall XR off pharmacy shelves.

Barba v. Shire: The Consumer Pay-for-Delay Case

In 2013, consumers filed a class action, Barba v. Shire US, Inc., in the Southern District of Florida. The plaintiffs alleged Shire violated the Sherman Act by maintaining an illegal monopoly on Adderall XR through a “pay-for-delay” scheme, claiming that Shire’s 2006 patent settlements with two generic manufacturers paid them to hold off launching generics until 2009. The complaint also alleged Shire’s original 2003 patent suits were sham litigation designed to block market entry and that Shire later restricted the supply of Adderall XR generic makers needed for development.⁵

In November 2016, Judge Joan A. Lenard approved a $14.75 million settlement covering more than 855,000 Adderall prescriptions across over 23,000 claims, calling the deal “reasonable and adequate” and overruling three objections.⁶⁵

Louisiana Wholesale Drug Co. v. Shire

A parallel antitrust case brought by wholesalers went the other way. Louisiana Wholesale Drug Company and Value Drug Company sued Shire in the Southern District of New York, arguing that Shire’s 2007 settlement agreements with Teva Pharmaceuticals and Impax Laboratories functioned as illegal “reverse payments” and that Shire had a duty to supply generic competitors.⁷

The district court dismissed the complaint, and in June 2014 the Second Circuit affirmed. The appeals court held that Shire’s alleged failure to fully supply competitors did not meet the legal threshold for an antitrust “duty to deal,” and noted that the plaintiffs had chosen not to argue the patent settlements themselves were anticompetitive, which narrowed the ruling.⁸

Generic Drug Price-Fixing Multidistrict Litigation

Adderall and other generics also appear in In re Generic Pharmaceuticals Pricing Antitrust Litigation (Case No. 2:16-MD-02724), pending in the Eastern District of Pennsylvania before Judge Cynthia M. Rufe. The suit alleges generic drug makers engaged in price-fixing, bid-rigging, and market allocation across numerous generic drugs.⁹

As of mid-2025, two settlements had been preliminarily approved: a $10 million deal with Heritage Pharmaceuticals and related entities, and a $48 million settlement with Apotex Corp., of which $17.6 million was allocated to consumers. A final fairness hearing was scheduled for October 2025, with claim distributions to follow any appeals. Litigation against the remaining defendants continues.⁹

Criminal Cases Against Telehealth Prescribers

The most recent Adderall cases target online prescribers rather than the drug’s manufacturer.

Done Global

Prosecutors say Done Global Inc., a California telehealth startup, turned online ADHD diagnosis into a distribution pipeline for more than 40 million pills of Adderall and other stimulants, generating over $100 million in revenue.¹⁰ According to the DEA, Done spent more than $40 million on social media advertising aimed at people seeking Adderall without a legitimate prescription and at individuals struggling during the COVID-19 pandemic. Its monthly subscription model allegedly shortened initial psychiatric appointments to less than half the standard duration, kept patients enrolled indefinitely, and used an “auto-refill” system that generated prescriptions without clinical interaction. In some instances, the system reportedly issued prescriptions to patients who had already died.¹¹

In November 2025, a federal jury in San Francisco convicted Done’s founder and CEO, Ruthia He, and its clinical president, David Brody, on charges of conspiracy to distribute controlled substances, distribution of controlled substances, and conspiracy to commit health care fraud. He was also convicted of conspiracy to obstruct justice. Prosecutors said she had moved operations to China, used encrypted messaging with disappearing messages, deleted evidence, and transferred funds to a Chinese shell company. Each defendant faced up to 20 years in prison, with sentencing set for February 2026.¹¹

In December 2025, a federal grand jury indicted the corporate entities themselves: Done Global Inc. and Mindful Mental Wellness P.A., a Florida medical practice that prosecutors said was created to bypass pharmacy blocks after pharmacies began refusing to fill Done-affiliated prescriptions. Done Global was charged with conspiracy to illegally distribute Adderall, four counts of illegal distribution, conspiracy to commit health care fraud, and conspiracy to obstruct justice.¹⁰

Cerebral

Cerebral Inc. reached a non-prosecution agreement with the U.S. Attorney’s Office for the Eastern District of New York in November 2024, resolving an investigation into its practices from 2019 through 2022. The government alleged Cerebral pressured providers to prescribe stimulants at extraordinarily high rates to retain subscribers and boost revenue.¹²

Internal targets required a 95% prescription rate after initial visits and a 100% rate for prescribing stimulants to ADHD patients. Supervisors received bonuses for hitting those numbers, and providers were paid an extra $10 per patient to perform required pre-prescription database checks for stimulant patients but not for other medical needs. Cerebral also admitted to poor controls against drug diversion, including failing to manage duplicate patient accounts that let some individuals obtain stimulants from multiple providers.¹²

Cerebral forfeited $3.65 million and faced an additional $2.92 million fine that was deferred due to the company’s financial condition and may be waived if Cerebral stays in compliance during the 30-month agreement. The company voluntarily stopped prescribing all controlled substances in October 2022, fired its former CEO, and is barred from prescribing controlled substances going forward.¹²

Cerebral’s pharmacy partner, Truepill, drew a separate enforcement action. In December 2022, the DEA issued an Order to Show Cause alleging Truepill had improperly filled over 72,000 controlled substance prescriptions between September 2020 and September 2022, 60% of which were for stimulants. The DEA said Truepill filled prescriptions that lacked a legitimate medical purpose, exceeded supply limits, or were written by prescribers without proper state licensing.¹³

Related ADHD-Drug Cases That Don’t Involve Adderall

A few high-profile enforcement actions get grouped with Adderall coverage but involve different medications. The FDA’s bioequivalence downgrades and proposed market removals in 2014–2016 concerned generic Concerta, not generic Adderall. A January 2025 Glenmark recall covered atomoxetine, and an Azurity recall the same month covered dextroamphetamine sulfate contaminated with an antihistamine.¹⁴ And the Texas Attorney General’s November 2025 $41.5 million settlement with Pfizer and Tris Pharma addressed adulterated Quillivant XR, not Adderall, though it reflects the same scrutiny of ADHD-drug manufacturers over quality controls and Medicaid billing.¹⁵ If you’re checking whether a recall or ruling affects your prescription, the drug name matters more than the ADHD label.

1
ClassAction.org. Adderall
2
Oshman Law. Adderall
3
U.S. Department of Justice. Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False Claims Act Allegations Relating to Drug Marketing and Promotion Practices
4
HHS Office of Inspector General. Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False Claims Act Allegations
5
Slack Davis. Barba et al v. Shire US Inc. et al
6
Law360. Barba et al v. Shire US Inc. et al
7
Applied Antitrust. In re Adderall XR Antitrust Litigation Corrected Brief of Plaintiffs-Appellants
8
FindLaw. Louisiana Wholesale Drug Co. v. Shire LLC
9
Generic Drugs End Payer Settlement. Long Form Notice – Heritage Apotex
10
U.S. Department of Justice. Digital Health Company and Medical Practice Indicted in $100M Adderall Distribution Scheme
11
U.S. Drug Enforcement Administration. Digital Health Company Cofounder/CEO and Clinical President Convicted in $100M Adderall Distribution Scheme
12
U.S. Department of Justice. Telehealth Company Cerebral Agrees to Pay Over $3.6 Million in Connection With Business Practices
13
U.S. Drug Enforcement Administration. DEA Serves Order to Show Cause to Truepill Pharmacy for Its Involvement in Unlawful Distribution of Controlled Substances
14
MedShadow. Investigating Generics: They Say Their ADHD Meds Aren’t Working. They’re Not Imagining It.
15
Texas Attorney General. Attorney General Paxton Secures $41.5 Million From Pfizer and Tris Pharma for Providing Adulterated Drugs